FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT ID: NCT03841110
Last Updated: 2023-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
37 participants
INTERVENTIONAL
2019-02-15
2022-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
NCT04847466
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
NCT05649618
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877
Immunotoxin Therapy in Treating Patients With Advanced Cancer
NCT00006981
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
NCT05451849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FT500 Monotherapy
FT500 administered once weekly for 3 weeks as a monotherapy
FT500
FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
Cyclophosphamide
Lympho-conditioning agent
Fludarabine
Lympho-conditioning agent
FT500 in Combination with Immune Checkpoint Inhibitor
FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
FT500
FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
Nivolumab
Immune Checkpoint Inhibitor
Pembrolizumab
Immune Checkpoint Inhibitor
Atezolizumab
Immune Checkpoint Inhibitor
Cyclophosphamide
Lympho-conditioning agent
Fludarabine
Lympho-conditioning agent
FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor
FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.
FT500
FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
Nivolumab
Immune Checkpoint Inhibitor
Pembrolizumab
Immune Checkpoint Inhibitor
Atezolizumab
Immune Checkpoint Inhibitor
Cyclophosphamide
Lympho-conditioning agent
Fludarabine
Lympho-conditioning agent
IL-2
Biologic response modifier
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FT500
FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
Nivolumab
Immune Checkpoint Inhibitor
Pembrolizumab
Immune Checkpoint Inhibitor
Atezolizumab
Immune Checkpoint Inhibitor
Cyclophosphamide
Lympho-conditioning agent
Fludarabine
Lympho-conditioning agent
IL-2
Biologic response modifier
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1A. Regimen A: FT500 Monotherapy (Dose Escalation): An advanced solid tumor malignancy, including lymphoma, in a participant who has failed or refused available FDA-approved therapies and is now a candidate for salvage therapy.
1B. Regimen B and BB (Dose Escalation): FT500 (+ IL-2, Regimen BB only) + ICI: An advanced solid tumor malignancy, including lymphomas, that has progressed on treatment with at least one ICI (ie, nivolumab, pembrolizumab or atezolizumab), in a participant who has also failed or refused other available approved therapies and is now a candidate for salvage therapy.
1C. Regimen B(Dose Expansion): FT500 (+ IL-2, Regimen BB only) + ICI An advanced solid tumor malignancy or lymphoma in a participant with disease relapse or progression on an ICI (nivolumab, pembrolizumab, or atezolizumab) in an approved indication per the respective USPI.
2\. Willingness to provide informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
3\. Age \>18 years old at the time of signing the ICF. 4. Presence of measurable disease by iRECIST or RECIL criteria, assessed before the start of lympho-conditioning and within 28 days prior to Day 1.
5\. Contraceptive use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
5a. Female participants: Women of childbearing potential (WOCBP) must use a highly effective form of contraception from the screening visit until at least 12 months after the final dose of CY, at least 4 months after the final dose of FT500, at least 4 months after the final dose of pembrolizumab, and at least 5 months after the final dose of nivolumab or atezolizumab, whichever is latest.
5b. Male participants: Males must be sterile (biologically or surgically) or use a highly effective method of contraception from the screening visit until at least 14 months after the final dose of CY, at least 6 months after the final dose of FT500, at least 6 months after the final dose of pembrolizumab, and at least 7 months after the final dose of nivolumab or atezolizumab, whichever is latest.
6\. Willingness to comply with study procedures through the planned study duration. For patients with \>1 measurable lesion, agreement to undergo a biopsy from a safely accessible site per Investigator assessment for exploratory biomarker assessments.
7\. Provision of signed and dated ICF to agree to participate, at time of withdrawal or completion of this study, in Fate Therapeutics' long-term, non-interventional, observational study, FT-003.
Exclusion Criteria
1\. Females who are pregnant or breastfeeding. 2. ECOG performance status ≥ 2. 3. Evidence of insufficient organ function as determined by any one of the following: 3a. Neutrophils \<1000/µL or platelets \<75,000/µL. 3b. Estimated creatinine clearance \<50 mL/minute (Cockcroft-gault). 3c. Total bilirubin \>2 x upper limit normal (ULN) with the exception of participants with Gilbert's Syndrome or known liver metastases.
3d. Aspartate aminotransferase (AST) \>3 x ULN, or alanine aminotransferase (ALT) \>3 x ULN. For participants with known liver metastases, AST or ALT \>5 x ULN.
3e. Oxygen saturation \<90% on room air. 3f. Left ventricular ejection fraction (LVEF) \<40% (eg by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan).
4.Receipt of any biological therapy, chemotherapy, or radiation (except palliative radiation) within 2 weeks prior to Day 1. Participants in Regimen B currently taking an ICI must interrupt ICI dosing at least 2 weeks prior to Day 1.
5\. CNS metastases that have not been treated; or treated CNS metastases that have not been stable for at least 4 weeks.
6\. Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first study medication; or the presence of unstable angina or congestive heart failure of New York Heart Association grade 2 or higher.
7\. Currently receiving or likely to require systemic immunosuppressive therapy (eg, prednisone \>5 mg daily) for any reason from Day -7 to Day 29.
8\. Uncontrolled infections. 9. Known allergy to the following FT500 components: Albumin (Human) or DMSO. 10. Presence of any medical or social issues that are likely to interfere with study conduct, or may cause increased risk to participant.
11\. Any medical condition or clinical laboratory abnormality that, per Investigator or Medical Monitor judgement, precludes safe participation in and completion of the study, or that could affect compliance with protocol conduct or interpretation of results. Participants who have had prior receipt of a Fate Therapeutics investigational human iPSC product may be eligible for the study with approval from the Medical Monitor.
11\. Participants who experienced an ICI-related adverse reaction that resulted in discontinuation of the ICI.
12\. Presence or history of autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma, Crohn's disease, ulcerative colitis), except for participants with isolated vitiligo, atopic dermatitis, controlled hypoadrenalism or hypopituitarism, and controlled thyroid disease.
13\. Participants who have received an allograft organ transplant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fate Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCSD Moores Cancer Center
San Diego, California, United States
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
Hackensack University Medical Center/John Theurer Cancer Center
Hackensack, New Jersey, United States
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FT500-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.